Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP

M. Takehara, M. Murakami, M. Inobe, K. Tanaka, Shunsuke Chikuma, I. Saito, Y. Kanegae, Y. Yasunami, M. Nakano, K. Yamashita, S. Todo, T. Uede

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

CTLA4IgG was shown to inhibit the costimulatory signal for T cell activation by interfering with the ligation of CD28 and B7-1 or B7-2. To inhibit various immune responses including acute cellular rejection of allografts, a certain level of serum CTLA4IgG should be maintained for an appropriate period. We previously reported on an adenovirus vector containing CTLA4IgG, which we designated Adex1CACTLA4IgG. Adex1CACTLA4IgG was able to maintain a significant level of serum CTLA4IgG for a long period on intravenous injection, which in turn inhibited various immune responses including protective immunity against infectious agents. To overcome the inhibitory effect, we constructed a new adenovirus vector, Adex1CALoxCTLA4IgGLox, by cloning CTLA4IgG cDNA between two loxP sequences under the control of the CAG promoter. We demonstrated that the administration of adenovirus vector containing Cre recombinase gene (Adex1CACre) at the desired time induced Cre-mediated recombination within a gene derived from Adex1CALoxCTLA4IgGLox vector, and the cDNA of CTLA4IgG was excised from the transduced gene and terminated the expression of CTLA4IgG in vitro and in vivo. More importantly, we also demonstrated that the long-term acceptance of allografts was achieved after the termination of CTLA4IgG expression, while the immune response against adenovirus was restored.

Original languageEnglish
Pages (from-to)415-426
Number of pages12
JournalHuman Gene Therapy
Volume12
Issue number4
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Adenoviridae
Allografts
Genes
Complementary DNA
Genetic Vectors
Serum
Intravenous Injections
Genetic Recombination
Ligation
Immunity
T-Lymphocytes
Gene Expression

ASJC Scopus subject areas

  • Genetics

Cite this

Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP. / Takehara, M.; Murakami, M.; Inobe, M.; Tanaka, K.; Chikuma, Shunsuke; Saito, I.; Kanegae, Y.; Yasunami, Y.; Nakano, M.; Yamashita, K.; Todo, S.; Uede, T.

In: Human Gene Therapy, Vol. 12, No. 4, 2001, p. 415-426.

Research output: Contribution to journalArticle

Takehara, M, Murakami, M, Inobe, M, Tanaka, K, Chikuma, S, Saito, I, Kanegae, Y, Yasunami, Y, Nakano, M, Yamashita, K, Todo, S & Uede, T 2001, 'Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP', Human Gene Therapy, vol. 12, no. 4, pp. 415-426. https://doi.org/10.1089/10430340150504037
Takehara, M. ; Murakami, M. ; Inobe, M. ; Tanaka, K. ; Chikuma, Shunsuke ; Saito, I. ; Kanegae, Y. ; Yasunami, Y. ; Nakano, M. ; Yamashita, K. ; Todo, S. ; Uede, T. / Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP. In: Human Gene Therapy. 2001 ; Vol. 12, No. 4. pp. 415-426.
@article{f95f19dd0cb0462a97abbb63caa918f2,
title = "Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP",
abstract = "CTLA4IgG was shown to inhibit the costimulatory signal for T cell activation by interfering with the ligation of CD28 and B7-1 or B7-2. To inhibit various immune responses including acute cellular rejection of allografts, a certain level of serum CTLA4IgG should be maintained for an appropriate period. We previously reported on an adenovirus vector containing CTLA4IgG, which we designated Adex1CACTLA4IgG. Adex1CACTLA4IgG was able to maintain a significant level of serum CTLA4IgG for a long period on intravenous injection, which in turn inhibited various immune responses including protective immunity against infectious agents. To overcome the inhibitory effect, we constructed a new adenovirus vector, Adex1CALoxCTLA4IgGLox, by cloning CTLA4IgG cDNA between two loxP sequences under the control of the CAG promoter. We demonstrated that the administration of adenovirus vector containing Cre recombinase gene (Adex1CACre) at the desired time induced Cre-mediated recombination within a gene derived from Adex1CALoxCTLA4IgGLox vector, and the cDNA of CTLA4IgG was excised from the transduced gene and terminated the expression of CTLA4IgG in vitro and in vivo. More importantly, we also demonstrated that the long-term acceptance of allografts was achieved after the termination of CTLA4IgG expression, while the immune response against adenovirus was restored.",
author = "M. Takehara and M. Murakami and M. Inobe and K. Tanaka and Shunsuke Chikuma and I. Saito and Y. Kanegae and Y. Yasunami and M. Nakano and K. Yamashita and S. Todo and T. Uede",
year = "2001",
doi = "10.1089/10430340150504037",
language = "English",
volume = "12",
pages = "415--426",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term acceptance of allografts by in vivo gene transfer of regulatable adenovirus vector containing CTLA4IgG and loxP

AU - Takehara, M.

AU - Murakami, M.

AU - Inobe, M.

AU - Tanaka, K.

AU - Chikuma, Shunsuke

AU - Saito, I.

AU - Kanegae, Y.

AU - Yasunami, Y.

AU - Nakano, M.

AU - Yamashita, K.

AU - Todo, S.

AU - Uede, T.

PY - 2001

Y1 - 2001

N2 - CTLA4IgG was shown to inhibit the costimulatory signal for T cell activation by interfering with the ligation of CD28 and B7-1 or B7-2. To inhibit various immune responses including acute cellular rejection of allografts, a certain level of serum CTLA4IgG should be maintained for an appropriate period. We previously reported on an adenovirus vector containing CTLA4IgG, which we designated Adex1CACTLA4IgG. Adex1CACTLA4IgG was able to maintain a significant level of serum CTLA4IgG for a long period on intravenous injection, which in turn inhibited various immune responses including protective immunity against infectious agents. To overcome the inhibitory effect, we constructed a new adenovirus vector, Adex1CALoxCTLA4IgGLox, by cloning CTLA4IgG cDNA between two loxP sequences under the control of the CAG promoter. We demonstrated that the administration of adenovirus vector containing Cre recombinase gene (Adex1CACre) at the desired time induced Cre-mediated recombination within a gene derived from Adex1CALoxCTLA4IgGLox vector, and the cDNA of CTLA4IgG was excised from the transduced gene and terminated the expression of CTLA4IgG in vitro and in vivo. More importantly, we also demonstrated that the long-term acceptance of allografts was achieved after the termination of CTLA4IgG expression, while the immune response against adenovirus was restored.

AB - CTLA4IgG was shown to inhibit the costimulatory signal for T cell activation by interfering with the ligation of CD28 and B7-1 or B7-2. To inhibit various immune responses including acute cellular rejection of allografts, a certain level of serum CTLA4IgG should be maintained for an appropriate period. We previously reported on an adenovirus vector containing CTLA4IgG, which we designated Adex1CACTLA4IgG. Adex1CACTLA4IgG was able to maintain a significant level of serum CTLA4IgG for a long period on intravenous injection, which in turn inhibited various immune responses including protective immunity against infectious agents. To overcome the inhibitory effect, we constructed a new adenovirus vector, Adex1CALoxCTLA4IgGLox, by cloning CTLA4IgG cDNA between two loxP sequences under the control of the CAG promoter. We demonstrated that the administration of adenovirus vector containing Cre recombinase gene (Adex1CACre) at the desired time induced Cre-mediated recombination within a gene derived from Adex1CALoxCTLA4IgGLox vector, and the cDNA of CTLA4IgG was excised from the transduced gene and terminated the expression of CTLA4IgG in vitro and in vivo. More importantly, we also demonstrated that the long-term acceptance of allografts was achieved after the termination of CTLA4IgG expression, while the immune response against adenovirus was restored.

UR - http://www.scopus.com/inward/record.url?scp=0035114921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035114921&partnerID=8YFLogxK

U2 - 10.1089/10430340150504037

DO - 10.1089/10430340150504037

M3 - Article

VL - 12

SP - 415

EP - 426

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 4

ER -